Postoperative breast irradiation: New trials needed in older patients

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1893-1894

  Kunkler, Ian ^a   Jack, Wilma ^a   Prescott, Robin ^a   Williams, Linda ^a   King, Celia ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

ADJUVANT THERAPY; AGED; AGING; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; NOTE; PATIENT CARE PLANNING; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; TUMOR RECURRENCE;

AGED; AGING; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PATIENT CARE PLANNING; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN;

EID: 0038134987     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.99.239     Document Type: Letter

References (7)

1. Efficace F, Bottomley A: Do quality-of-life randomized clinical trials support clinicians in their decision-making? J Clin Oncol 20:4126-4127, 2002.
2. Levine MN, Ganz PA: Reply: Do quality-of-life randomized clinical trials support clinicians in their decision-making? J Clin Oncol 20:4127- 4128, 2002.
3. Levine MN, Ganz PA: Beyond the development of quality-of-life instruments: Where do we go from here? J Clin Oncol 20:2215-2216, 2002.
4. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679, 1996.
5. Panzini I, Tassinari D, Gianni L, et al: Quality of life assessment in controlled clinical trials: A critical review of literature. Ann Oncol 13:65, 2002 (suppl 3, abstr D68).
6. Burris III HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997.
7. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: A Canadian randomized trial with palliative end point. J Clin Oncol 14:1756-1764, 1996.